Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-011: V940 + BCG vs BCG in High-risk NMIBC
NCT06833073Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- Sep 2031
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 19
01
Overview
A Phase 2 trial of intismeran autogene in non-muscle-invasive bladder cancer (NMIBC), sponsored by Merck & Co.. Started Mar 2025; status: recruiting.
02
Drugs
intismeran autogene
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06833073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833073.